Kyungjin Peter Kim – CEO, ST Pharm, South Korea
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Parexel International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, Parexel has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of Parexel, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.
Corporate Structure
The Company is managed through three business segments: Clinical Research Services (CRS), Parexel Consulting and Medical Communications Services (PCMS), and Perceptive Informatics.
CRS constitutes the Company’s core business and includes Phase I – IV clinical trials management and biostatistics, data management and clinical pharmacology, as well as related medical advisory and investigator site services.
PCMS provides technical expertise in such disciplines as regulatory affairs, industry training, publishing, product development, management consulting, registration, commercialization issues, market development, targeted communications services in support of product launch, as well as health policy consulting and strategic reimbursement services.
Perceptive Informatics provides information technology solutions designed to improve clients’ product development processes. Perceptive offers a portfolio of products and services that includes medical imaging services, interactive voice response systems (“IVRS”), clinical trials management systems (“CTMS”), web-based portals, systems integration, and patient diary applications.
Contact Details
PAREXEL International Co., LTD
18F Haesung Building, 504
Teheran-Ro, Gangnam-Gu
Seoul, Korea 135-725
서울시 강남구 대치동 942 해성빌딩18층 135-725
Phone: +82 (0) 2 3453 8838
Fax: +82 (0) 2 3453 8839
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
See our Cookie Privacy Policy Here
